Aeterna's AEZS-108 final Phase 2 results in endometrial cancer to be presented at ESGO 2011

NewsGuard 100/100 Score
Jul 19 2011

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company")  today announced that final Phase 2 results in endometrial cancer on its anticancer compound, AEZS-108, will be presented during a poster session at the upcoming 17th International Meeting of the European Society of Gynaecological Oncology ("ESGO"), to be held September 11-14, 2011, at the Milan Convention Center in Milan, Italy.

The trial was conducted by the German AGO Study Group and study centers in Bulgaria. AEZS-108, a targeted cytotoxic peptide conjugate, is currently in Phase 1/2 programs in prostate and bladder cancer, and has successfully completed Phase 2 trials in endometrial and ovarian cancer.

Source:

AETERNA ZENTARIS INC.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Study reveals vascular health disparities between Black and white men with prostate cancer diagnosis
Three early-phase clinical studies show promising initial data for patients with lymphoma, gastric cancers
New cancer projections show increased prostate cases by 25% in 2050, despite prevention efforts
Cancer risk elevated in families with male infertility
Linking lifestyle to longevity: How diet and hypertension sway risks for heart disease and cancer
New lab assay could make diagnosis and treatment of lung cancer easier
Depression impacts survival rates and quality of life for women with breast cancer
NCCN 2024 Annual Conference focuses on practical applications for improving cancer care

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Expanding research and clinical options for children with cancer